The American Cancer Society National Lung Cancer Roundtable strategic plan: Introduction.
early detection of cancer
lung cancer screening
lung neoplasms
mass screening
standard of care
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
20 Sep 2024
20 Sep 2024
Historique:
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
20
9
2024
Statut:
aheadofprint
Résumé
Lung cancer is the leading cause of cancer death in the United States and across the world. The American Cancer Society National Lung Cancer Roundtable (ACS NLCRT) was established in 2017 as a consortium of public, private, and voluntary organizations with a mission to lower the impact of lung cancer via prevention, early detection, and optimal therapy. The ACS NLCRT supports a comprehensive scope of work that covers the lung cancer continuum, from risk reduction, tobacco prevention and control, and early detection (screening and incidental lung nodule management) to guideline-based staging, biomarker testing, treatment, and survivorship and overarching issues such as stigma and nihilism, health equity, and tactical approaches such as state coalition efforts and policy initiatives. Applying a multidimensional and multisector approach, over 220 public, private, and government agency member organizations and 250 volunteer experts, patients, and caregiver advocate representatives collaborate to address challenges across the lung cancer continuum by catalyzing action to conceive, build, and strengthen innovative solutions. The wide-ranging membership allows the ACS NLCRT to harness the collective power and expertise of the entire lung cancer community by connecting leaders, communities, and systems to improve equity and access. These national, state, and local relationships provide partnerships for the dissemination of ACS NLCRT-developed tools and resources. This article describes the ACS NLCRT and introduces the series of accompanying and future articles that together make up the ACS NLCRT strategic plan, which provides a roadmap for future research, investment, and collaboration to reduce lung cancer mortality and lung cancer-related stigma and enhance survivorship.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : American Cancer Society National Lung Cancer Roundtable
Informations de copyright
© 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
American Cancer Society Roundtables. American Cancer Society. Accessed October 1, 2023. https://www.cancer.org/about‐us/our‐partners/american‐cancer‐society‐roundtables.html
Levin B, Smith RA, Feldman GE, et al. Promoting early detection tests for colorectal carcinoma and adenomatous polyps: a framework for action: the strategic plan of the National Colorectal Cancer Roundtable. Cancer. 2002;95(8):1618‐1628. doi:10.1002/cncr.10890
Human Vaccines & Immunotherapeutics Collection Toolkit. American Cancer Society National HPV Vaccination Roundtable, American Cancer Society; 2023. HPV‐RT‐HVI‐Supplement‐Toolkit_‐Final‐v2.pdf, Accessed June 4, 2024. https://www.hpvroundtable.org
Webinar: Field Strategies to Increase Colorectal Cancer Screening and Promote Colorectal Cancer Health Equity in Communities Across the US. American Cancer Society National Colorectal Cancer Roundtable, American Cancer Society. Updated January 24, 2023. Accessed November 20, 2023. https://nccrt.org/resource/webinar‐field‐strategies‐to‐increase‐colorectal‐cancer‐screening/
Co‐Brandable “Start at Age 9” Social Media Graphics. American Cancer Society National HPV Vaccination Roundtable, American Cancer Society; 2023. Accessed October 30, 2023. https://hpvroundtable.org/resource‐center/?type=59&audience=37
Steps for Increasing Colorectal Cancer Screening Rates: A Manual for Primary Care Practices. American Cancer Society National Colorectal Cancer Roundtable, American Cancer Society; 2022. Accessed November 1, 2023. https://nccrt.org/resource/steps‐for‐increasing‐crc‐screening‐rates‐2022/
Colonoscopy Needs Calculator. American Cancer Society National Colorectal Cancer Roundtable, American Cancer Society. Updated June 2023. Accessed November 14, 2023. https://learning.nccrt.org/colonoscopy‐calculator‐form/
Arora S, Geppert CM, Kalishman S, et al. Academic health center management of chronic diseases through knowledge networks: Project ECHO. Acad Med. 2007;82(2):154‐160. doi:10.1097/ACM.0b013e31802d8f68
Reiter PL, Gerend MA, Gilkey MB, et al. Advancing human papillomavirus vaccine delivery: 12 priority research gaps. Acad Pediatr. 2018;18(suppl 2):S14‐S16. doi:10.1016/j.acap.2017.04.023
Dwyer AJ, Wender RC, Weltzien ES, et al. Collective pursuit for equity in cancer care: the National Navigation Roundtable. Cancer. 2022;128(suppl 13):2561‐2567. doi:10.1002/cncr.34162
Wender R, Brooks D, Sharpe K, Doroshenk M. The National Colorectal Cancer Roundtable: past performance, current and future goals. Gastrointest Endosc Clin N Am. 2020;30(3):499‐509. doi:10.1016/j.giec.2020.02.013
Wender RC, Doroshenk M, Brooks D, Hotz J, Smith RA. Creating and implementing a national public health campaign: the American Cancer Society's and National Colorectal Cancer Roundtable's 80% by 2018 initiative. Am J Gastroenterol. 2018;113(12):1739‐1741. doi:10.1038/s41395‐018‐0384‐1
Joseph DA, King JB, Dowling NF, Thomas CC, Richardson LC. Vital signs: colorectal cancer screening test use—United States, 2018. MMWR Morb Mortal Wkly Rep. 2020;69(10):253‐259. doi:10.15585/mmwr.mm6910a1
80% in Every Community Strategic Plan. American Cancer Society National Colorectal Cancer Roundtable, American Cancer Society. Accessed October 1, 2023. https://nccrt.org/our‐impact/80‐in‐every‐community/strategic‐plan/
Closing Gaps in Cancer Screening: Connecting People, Communities, and Systems to Improve Equity and Access. A Report from the President’s Cancer Panel to the President of the United States. President’s Cancer Panel; 2022. Accessed November 1, 2023. https://PresCancerPanel.cancer.gov/report/cancerscreening/
Closing Gaps in Cancer Screening: Connecting People, Communities, and Systems to Improve Equity and Access: Lung Cancer Companion Brief. A Report from the President’s Cancer Panel to the President of the United States. President’s Cancer Panel; 2022. Accessed November 1, 2023. https://prescancerpanel.cancer.gov/report/cancerscreening/pdf/PresCancerPanel_CancerScreening_CB_Lung_Feb2022.pdf
Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123(suppl 1):21S‐49S. doi:10.1378/chest.123.1_suppl.21s
Cancer Facts & Figures 2023. American Cancer Society; 2023. Accessed November 1, 2023. https://www.cancer.org/content/dam/cancer‐org/research/cancer‐facts‐and‐statistics/annual‐cancer‐facts‐and‐figures/2023/2023‐cancer‐facts‐and‐figures.pdf
Wingo PA, Cardinez CJ, Landis SH, et al. Long‐term trends in cancer mortality in the United States, 1930–1998. Cancer. 2003;97(suppl 12):3133‐3275. doi:10.1002/cncr.11380
Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database:Mortality‐All Causes of Death, Total U.S. (1969–2020) (underlying mortality data provided by the National Center for Health Statistics). National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2022.
Centers for Disease Control and Prevention. Achievements in public health, 1900‐1999: Tobacco Use – United States, 1900‐1999. MMWR 1999;48(43):986‐993. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm4843a2.htm
Wang TW, Kenemer B, Tynan MA, Singh T, King B. Consumption of combustible and smokeless tobacco — United States, 2000–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1357‐1363. doi:10.15585/mmwr.mm6548a1
Cancer Facts & Figures 2022. American Cancer Society; 2022. Accessed November 1, 2023. http://www.cancer.org/research/cancer‐facts‐statistics/all‐cancer‐facts‐figures/cancer‐facts‐figures‐2022.html
Data from: SEER*Stat Database: Mortality—All COD, Total U.S. (1969–2019), Katrina/Rita Population Adjustment. Total U.S., 1969–2019 Counties. Surveillance, Epidemiology, and End Results Program. Released April 2021.
Jeon J, Holford TR, Levy DT, et al. Smoking and lung cancer mortality in the United States from 2015 to 2065: a comparative modeling approach. Ann Intern Med. 2018;169(10):684‐693. doi:10.7326/M18‐1250
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12‐49. doi:10.3322/caac.21820
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7‐33. doi:10.3322/caac.21708
Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68(1):31‐54. doi:10.3322/caac.21440
Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. US Public Health Service; 1964.
Smoking Cessation: A Report of the Surgeon General. US Department of Health and Human Services; 2020. Accessed November 4, 2023. https://www.hhs.gov/sites/default/files/2020‐cessation‐sgr‐full‐report.pdf
Preventing Tobacco Use Among Youth and Young Adults: A Report of the Surgeon General. PsycExtra Dataset. US Department of Health and Human Services; 2012. doi:10.1037/e603152012‐001
Health, United States, 2017: With Chartbook on Long‐Term Trends in Health. National Center for Health Statistics; 2018.
National Health Interview Survey. Questionnaires, Datasets, and Related Documentation. National Center for Health Statistics. Accessed October 16, 2023. https://www.cdc.gov/nchs/nhis/nhis_questionnaires.htm
Burden of Cigarette Use in the U.S. Centers for Disease Control and Prevention. Updated May 4, 2023. Accessed September 2, 2023. https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette‐smoking‐in‐united‐states.html#:~:text=Cigarette%20smoking%20kills%20more%20than%20480%2C000%20Americans%20each%20year.&text=Cigarette%20smoking%20cost%20the%20United,%24372%20billion%20in%20lost%20productivity
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17‐48. doi:10.3322/caac.21763
Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review (CSR) 1975–2015. Accessed November 1, 2023. https://seer.cancer.gov/archive/csr/1975_2015/index.html#contents
National Lung Screening Trial Research Team. Reduced lung‐cancer mortality with low‐dose computed tomographic screening. N Engl J Med. 2011;365(5):395‐409. doi:10.1056/NEJMoa1102873
de Koning HJ, vander Aalst CM, de Jong PA, et al. Reduced lung‐cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503‐513. doi:10.1056/NEJMoa1911793
Wender R, Fontham ET, Barrera E Jr, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63(2):107‐117. doi:10.3322/caac.21172
Moyer VA, U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330‐338. doi:10.7326/M13‐2771
Krist AH, Davidson KW, Mangione CM, et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962‐970. doi:10.1001/jama.2021.1117
Clinical Preventive Service Recommendation: Lung Cancer. American Academy of Family Physicians; 2022. Accessed December 1, 2022. https://www.aafp.org/family‐physician/patient‐care/clinical‐recommendations/all‐clinical‐recommendations/lung‐cancer.html
Mazzone PJ, Silvestri GA, Souter LH, et al. Screening for lung cancer: CHEST guideline and expert panel report. Chest. 2021;160(5):e427‐e494. doi:10.1016/j.chest.2021.06.063
Wood DE, Kazerooni EA, Aberle D, et al. NCCN Guidelines® insights: lung cancer screening, version 1.2022. J Natl Compr Cancer Netw. 2022;20(7):754‐764. doi:10.6004/jnccn.2022.0036
Wolf AMD, Oeffinger KC, Shih Y‐CT, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2023;74(1):50‐81. doi:10.3322/caac.21811
Bastani M, Chiuzan C, Silvestri G, et al. A predictive model for lung cancer screening nonadherence in a community setting health‐care network. JNCI Cancer Spectr. 2023;7(2):pkad019. doi:10.1093/jncics/pkad019
Silvestri GA, Goldman L, Burleson J, et al. Characteristics of persons screened for lung cancer in the United States: a cohort study. Ann Intern Med. 2022;175(11):1501‐1505. doi:10.7326/M22‐1325
Bastani M, Patel D, Silvestri GA, Raoof S, Chusid J, Cohen SL. Factors associated with lung cancer screening adherence among patients with negative baseline CT results in a community health care setting. J Am Coll Radiol. 2022;19(2)(pt A):232‐239. doi:10.1016/j.jacr.2021.10.010
Lozier JW, Fedewa SA, Smith RA, Silvestri GA. Lung cancer screening eligibility and screening patterns among Black and White adults in the United States. JAMA Netw Open. 2021;4(10):e2130350. doi:10.1001/jamanetworkopen.2021.30350
Rivera MP, Henderson LM, Sakoda LC. Delays in follow‐up after a positive lung cancer screening exam: is the benefit of screening compromised? Ann Am Thorac Soc. 2023;20(8):1102‐1104. doi:10.1513/AnnalsATS.202305‐440ED
Ahmed A, Hippe DS, Snidarich M, Crothers K, Triplette M. Delays in recommended follow‐up after positive findings in lung cancer screening. Ann Am Thorac Soc. 2023;20(8):1175‐1181. doi:10.1513/AnnalsATS.202210‐891OC
Kee D, Sigel KM, Wisnivesky JP, Kale MS. Timely adherence to follow‐up after high‐risk lung cancer screenings. J Med Screen. 2023;30(3):150‐155. doi:10.1177/09691413231162507
Fedewa SA, Kazerooni EA, Studts JL, et al. State variation in low‐dose computed tomography scanning for lung cancer screening in the United States. J Natl Cancer Inst. 2021;113(8):1044‐1052. doi:10.1093/jnci/djaa170
Bandi P, Star J, Ashad‐Bishop K, Kratzer T, Smith RA, Jemal A. Lung cancer screening in the United States, 2022. JAMA Intern Med. 2024;84(8):882‐891. doi:10.1001/jamainternmed.2024.1655
Ma J, Ward EM, Smith R, Jemal A. Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer. 2013;119(7):1381‐1385. doi:10.1002/cncr.27813
Rivera MP, Katki HA, Tanner NT, et al. Addressing disparities in lung cancer screening eligibility and healthcare access. An official American Thoracic Society statement. Am J Respir Crit Care Med. 2020;202(7):e95‐e112. doi:10.1164/rccm.202008‐3053ST
Sahar L, Douangchai Wills VL, Liu KKA, et al. Geographic access to lung cancer screening among eligible adults living in rural and urban environments in the United States. Cancer. 2022;128(8):1584‐1594. doi:10.1002/cncr.33996
Carter‐Harris L, Ceppa DP, Hanna N, Rawl SM. Lung cancer screening: what do long‐term smokers know and believe? Health Expect. 2017;20(1):59‐68. doi:10.1111/hex.12433
Zgodic A, Zahnd WE, Miller DP Jr, Studts JL, Eberth JM. Predictors of lung cancer screening utilization in a population‐based survey. J Am Coll Radiol. 2020;17(12):1591‐1601. doi:10.1016/j.jacr.2020.06.015
Sharma A, Kasza K, Hyland A, et al. Awareness and interest in lung cancer screening among current and former smokers: findings from the ITC United States survey. Cancer Causes Control. 2019;30(7):733‐745. doi:10.1007/s10552‐019‐01186‐y
Steinberg MB, Young WJ, Miller Lo EJ, et al. Electronic health record prompt to improve lung cancer screening in primary care. Am J Prev Med. 2023;65(5):892‐895. doi:10.1016/j.amepre.2023.05.016
Hochheimer CJ, Sabo RT, Tong ST, et al. Practice, clinician, and patient factors associated with the adoption of lung cancer screening. J Med Screen. 2021;28(2):158‐162. doi:10.1177/0969141320937326
Melzer AC, Golden SE, Ono SS, Datta S, Triplette M, Slatore CG. “We just never have enough time”: clinician views of lung cancer screening processes and implementation. Ann Am Thorac Soc. 2020;17(10):1264‐1272. doi:10.1513/AnnalsATS.202003‐262OC
Coughlin JM, Zang Y, Terranella S, et al. Understanding barriers to lung cancer screening in primary care. J Thorac Dis. 2020;12(5):2536‐2544. doi:10.21037/jtd.2020.03.66
Abubaker‐Sharif M, Shusted C, Myers P, Myers R. Primary care physician perceptions of shared decision making in lung cancer screening. J Cancer Educ. 2020;37(4):1099‐1107. doi:10.1007/s13187‐020‐01925‐9
Ettinger DS, Wood DE, Aisner DL, et al. NCCN Guidelines® insights: non‐small cell lung cancer, version 2.2023. J Natl Compr Cancer Netw. 2023;21(4):340‐350. doi:10.6004/jnccn.2023.0020
Non‐Small Cell Lung Cancer, Version 1.2024—December 21, 2023. National Comprehensive Cancer Network. Updated December 21, 2023. Accessed January 12, 2023. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
Khorfan R, Cooke DT, Meguid RA, et al. Institutional factors associated with adherence to quality measures for stage I and II non‐small cell lung cancer. J Thorac Cardiovasc Surg. 2021;162(3):649‐660.e8. doi:10.1016/j.jtcvs.2020.05.123
Henderson LM, Farjah F, Detterbeck F, Smith RA, Silvestri GA, Rivera MP. Pretreatment invasive nodal staging in lung cancer: knowledge, attitudes, and beliefs among academic and community physicians. Chest. 2021;161(3):826‐832. doi:10.1016/j.chest.2021.11.010
Farjah F, Tanner NT. Mediastinal staging for lung cancer. Chest. 2021;160(4):1552‐1559. doi:10.1016/j.chest.2021.05.009
Farjah F, Silvestri GA, Wood DE. Commentary: Invasive mediastinal staging for lung cancer—quality gap, evidence gap, both? J Thorac Cardiovasc Surg. 2019;158(4):1232‐1233. doi:10.1016/j.jtcvs.2019.05.016
Shen H, Wang X, Nie Y, et al. Minimally invasive surgery versus thoracotomy for resectable stage II and III non‐small‐cell lung cancers: a systematic review and meta‐analysis. Eur J Cardiothorac Surg. 2021;59(5):940‐950. doi:10.1093/ejcts/ezaa437
Altorki N, Wang X, Kozono D, et al. Lobar or sublobar resection for peripheral stage IA non‐small‐cell lung cancer. N Engl J Med. 2023;388(6):489‐498. doi:10.1056/NEJMoa2212083
Andruska N, Stowe HB, Crockett C, et al. Stereotactic radiation for lung cancer: a practical approach to challenging scenarios. J Thorac Oncol. 2021;16(7):1075‐1085. doi:10.1016/j.jtho.2021.04.002
Deb D, Moore AC, Roy UB. The 2021 global lung cancer therapy landscape. J Thorac Oncol. 2022;17(7):931‐936. doi:10.1016/j.jtho.2022.03.018
Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted therapy in advanced non‐small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021;14(1):108. doi:10.1186/s13045‐021‐01121‐2
Mithoowani H, Febbraro M. Non‐small‐cell lung cancer in 2022: a review for general practitioners in oncology. Curr Oncol. 2022;29(3):1828‐1839. doi:10.3390/curroncol29030150
Robert NJ, Espirito JL, Chen L, et al. Biomarker testing and tissue journey among patients with metastatic non‐small cell lung cancer receiving first‐line therapy in the US Oncology Network. Lung Cancer. 2022;166:197‐204. doi:10.1016/j.lungcan.2022.03.004
Fox AH, Nishino M, Osarogiagbon RU, et al. Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: a National Lung Cancer Roundtable best‐practice guide. CA Cancer J Clin. 2023;73(4):358‐375. doi:10.3322/caac.21774
Fox AH, Jett JR, Roy UB, et al. Knowledge and practice patterns among pulmonologists for molecular biomarker testing in advanced non‐small cell lung cancer. Chest. 2021;160(6):2293‐2303. doi:10.1016/j.chest.2021.06.027
Mileham KF, Schenkel C, Bruinooge SS, et al. Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: results of a survey of U.S. oncologists. Cancer Med. 2022;11(2):530‐538. doi:10.1002/cam4.4459
Kim ES, Roy UB, Ersek JL, et al. Updates regarding biomarker testing for non‐small cell lung cancer: considerations from the National Lung Cancer Roundtable. J Thorac Oncol. 2019;14(3):338‐342. doi:10.1016/j.jtho.2019.01.002
Decision Memo: Screening for Lung Cancer with Low Dose Computed Tomography (LDCT): CAG‐00439N. Centers for Medicare and Medicaid Services. Updated February 5, 2015. Accessed April 16, 2021. https://www.cms.gov/medicare‐coverage‐database/details/nca‐decision‐memo.aspx?NCAId=274
Lung Cancer Screening/Nodule Management: An Approach to Financial Modeling and Forecasting. American Cancer Society National Lung Cancer Roundtable, American Cancer Society; 2023. Accessed January 11, 2024. https://nlcrt.org/wp‐content/uploads/LungPLAN‐Overview‐Brochure.pdf
Sarfaty M, Myers RE. The effect of HEDIS measurement of colorectal cancer screening on insurance plans in Pennsylvania. Am J Manag Care. 2008;14:277‐282.
New Measure Coming for Lung Cancer Screening. National Committee for Quality Assurance. Accessed March 12, 2022. https://www.ncqa.org/blog/new‐measure‐coming‐for‐lung‐cancer‐screening/#:~:text=New%20HEDIS%20Measure%20in%20Development&text=The%20NCQA%20effort%20is%20building,age%2050%2C%20through%20age%2080